Heron Therapeutics (HRTX) Receives CRL for HTX-011 for Management of Postoperative Pain

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. NVDA
2. CRWV
3. SPY
4. EYPT
5. TSLA
6. SLN
7. SLGN
8. CLF
9. IRON
10. MANE

Go back to Heron Therapeutics (HRTX) Receives CRL for HTX-011 for Management of Postoperative Pain

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

June 29, 2020 8:45 AM EDT

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on June 26, 2020 regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

The CRL stated that the FDA is unable to approve the NDA in its present form based on the... More